Essa is a clinical-stage pharmaceutical company focused on developing novel and proprietary therapies for the treatment of prostate cancer.
Prostate cancer is predominantly driven by the androgen receptor (AR). The current standard of care antiandrogen therapies target one end of the receptor (the ligand binding domain), which can eventually lead to treatment resistance. Our lead candidate, masofaniten (formerly EPI-7386), is a highly selective, oral, small molecule that inhibits the N-terminal domain of the AR, which is located on the opposite end of the receptor and is not targeted by any antiandrogen therapy.
Masofaniten is in development in combination with antiandrogen treatments in patients with prostate cancer who are earlier in their course of the disease. Through deeper and broader inhibition of androgen-induced biology, combination therapy may provide additional benefit to prostate cancer patients than current antiandrogen therapy.